Based on the genetic profile of each individual, we construct a biomathematical model of the human body. Utilizing this acquired data, we develop personalized precision medications for each person, which will be manufactured at our exceptional pharmaceutical facilities.

Coin picture


Michael Kofman photo
Michael Kofman
Digital Invest Inc.

Dear Investor,

We invite you to embark on a transformative journey at the forefront of cutting-edge medical advancements. Our company is dedicated to instigating profound changes in the field of genetics and human genome research, paving the way for a healthier and more prosperous future. With a proven track record in commercialization and a team boasting extensive experience in the field, we are poised to lead the charge in reshaping the landscape of healthcare.

The central focus of our innovative project, The Biomath Life Platform, revolves around harnessing the power of genetics, genetic engineering, and biotechnology, as well as leveraging Cloud Computing and Artificial Intelligence to drive breakthroughs in personalized medicine. Collaborating closely with scientists and biomathematicians from esteemed medical schools, we delve deep into the intricacies of human genetic makeup, uncovering the hidden secrets within our DNA. This enables us to comprehend and rectify biomolecular defects at their root. Through sophisticated biomathematical modeling of the human body, we develop an unparalleled grasp of its intricate interplay, ushering in a new era of Precision Medicine.

Imagine a world where medical treatments and medicines are tailored to each individual's genetic profile, ensuring the highest efficacy and minimizing adverse effects. Our advancements in gene engineering, combined with Cloud Computing and Artificial Intelligence, empower us to rapidly diagnose diseases and accurately predict their development, thereby transforming the management of illnesses. This not only enhances the quality of life but also extends human lifespans, nurturing healthier generations for years to come.

At the core of our success lies an unwavering commitment to innovation. Our meticulously tested and refined solutions form the bedrock of our endeavors. By harnessing the potential of Cloud Computing and Artificial Intelligence, we optimize research processes, enabling us to develop novel therapies and treatments more swiftly than ever before. These same results will also form the basis of our first fully automated pharmaceutical factory for the production of personalized medicines.

By investing in our venture, you are not only supporting a dynamic team with a wealth of experience but also driving the transformation of healthcare on a global scale. Together, we can elevate the standards of medical care, ushering in a new era of health, well-being, and longevity.

Join us in shaping the future of healthcare—a future where innovation, technology, and genetics converge to create a world of boundless possibilities. Together, let's elevate our business to unparalleled heights of efficiency and effectiveness, all while making a lasting impact on the lives of countless individuals.

Thank you for your attention. We look forward to your response and the possibility of collaboration.

Michael Kofman
Digital Invest Inc.



Digital Invest Inc. presents an innovative, comprehensive solution to the pressing challenges of Precision Medicine for the people worldwide. This solution aims to bring together all the necessary components of the project, from adapting the results of genomic research to their practical application by physicians, to the production of personalized medications for each individual patient and integration with insurance companies, public and private medical institutions, within a unified and efficient business structure.

The Biomath Life Platform

Our vision

We were looked at as dreamers and visionaries in 2008, 2010, 2013, as we presented our ideas. But there were people who believed in them and they were not mistaken. Now we have returned with a new idea! Not just an idea, but an IDEA backed by those very solutions that seemed unimaginable at the time, without any precedents to refer to.

Time to reap. The experience we have gained in creating advanced human DNA profiles and the practically limitless computational capabilities of Cloud Technologies, combined with the modern advancements in biomathematics, medically oriented Artificial Intelligence, and the immense amount of accumulated genetic information, have brought us to the threshold of a completely new, groundbreaking project to create a biomathematical model of the human body.

For what purpose, you may ask.

In a nutshell. The human body is an incredibly complex and finely balanced system. Any disruption in one organ affects the efficiency of others to varying degrees. Such imbalance makes it challenging to identify the cause, the "weak link." Often, it's only the second or third organ in the chain that manifests external symptoms and shows up in test results. From our perspective, pinpointing the culprit is akin to a detective investigation. However, diseases often leave us with little time, resulting in serious and sometimes irreversible consequences. Attempts to make an accurate diagnosis and prescribe the right medications are often too time-consuming compared to the pace at which the disease progresses, leading to irreversible situations.


Digital Invest Inc., a company with many years of experience in research, development and commercialization of advanced technologies, including biomolecular research, diagnostics and precision medicine based on the analysis of the human genome.

The company boasts a team of seasoned specialists and managers, each with extensive expertise in spearheading groundbreaking ventures. Our collective experience spans diverse domains such as genetic testing, Cloud-based Processing of Big Data, Artificial Intelligence, telecommunications, e-Commerce, data security, and more, including the successful establishment of international enterprises.

Currently, our primary objective is to leverage our amassed knowledge and expertise to undertake a comprehensive Precision Medicine initiative. Our professionals possess a proven track record of implementing similar projects on a bi-national scale, and now is the opportune moment to apply this invaluable experience for the betterment of United States citizens and people worldwide.



Michael Kofman photo

Michael Kofman


is a renowned technological visionary known for his dynamic approach to understanding the ever-evolving needs of today's complex market. His expertise encompasses executive acumen, strategic analysis of emerging technologies and markets, information security/privacy, research and development, marketing, administration, and investment banking.

As an entrepreneur, board member, and advisor for both public and private companies, Michael Kofman has successfully founded several companies in the United States and Europe. Notably, he has recently been involved with BioTechnology Group, Inc., a company dedicated to DNA testing and analysis, process automation for genetic services, and comprehensive human genetic research. Mr. Kofman firmly believes that the life sciences sector, combined with the latest technological advancements, presents exponential possibilities.

In 1997, Mr. Kofman founded 9 Net Avenue, Inc., which grew to become one of the world's largest hosting companies. In 1999, 9 Net Avenue was acquired by Concentric Networks (NASDAQ: CNTX), subsequently acquired by XO Communications (NASDAQ: XOXO), with a maximum market value of $19.5 billion.

In recognition of his outstanding achievements in business creation and development, Mr. Kofman was honored as Entrepreneur of the Year by "Entrepreneur Magazine" in 1999. Since 2000, his exceptional achievements have consistently been recognized and listed in the esteemed publications of Who's Who in America, World, Science, and Engineering.

Alex Tur photo

Alex Tur


is accomplished and proactive product ownership professional with an extensive background holding high-level positions. His proven leadership acumen in managing both internal and outsourced international teams, fostering the development of interconnected products. Mr. Tur is adept at unraveling complex ideation challenges and devising innovative implementation strategies for corporate clients and startups across diverse sectors such as e-Commerce, Cloud Computing, Healthcare and more. Also, over 20 years of hands-on experience in multidisciplinary software and hardware development are in his background.

In particular, as a CEO & co-founder, Mr. Alex Tur developed and launched the innovative Cloud B2B/B2C Platform to aggregate and process Big Data in a single ecosystem. The platform also allows various providers and consumers to perform a massive search for the required information in context and exchange unstructured data in the formats most familiar to each of them.

From 2010-2014, Mr. Alex Tur worked for BioTechnology Group, Inc. as Director of Research and Development, led several Agile development teams, teams of engineers, doctors, geneticists, sales managers, partners, stakeholders in several countries, consolidated and directed their efforts to achieve their goals.

As Director of Research and Development, Mr. Alex Tur led the development of projects on video surveillance system and the system of highly reliable transmission and storage data for Xibi Group Inc.


GENEX Inc., 2010

Drop Us a Line

We'll be happy to communicate with you.


Find Us on Map

301 S McDowell Street, Suite 125 - 1609, Charlotte, NC 28204, United States

We use performance cookies. Cookies help us deliver the best experience on our website. By using our website, you agree to the use of cookies.